NCT02193152View on ClinicalTrials.gov

Pazopanib in Molecularly Selected Patients With Advanced NSCLC

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 27, 2015

Primary Completion Date

December 24, 2019

Study Completion Date

December 24, 2019

Conditions
Carcinoma, Non-Small Cell LungNon-Small Cell Lung CancerNonsmall Cell Lung Cancer
Interventions
DRUG

Pazopanib

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Washington University School of Medicine

OTHER